LLY NYSE
Eli Lilly and Company
1W: +3.7%
1M: +13.1%
3M: +3.2%
YTD: -3.4%
1Y: +40.0%
3Y: +142.9%
5Y: +454.8%
$1,065.00
+23.35 (+2.24%)
Weekly Expected Move ±6.5%
$874
$940
$1005
$1070
$1136
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.90
Bullish
4 bullish
0 neutral
0 bearish
Articles (24h)
4
Hourly Sentiment (24h)
0.50
Bullish
19 bullish
1 neutral
5 bearish
Articles (7d)
25
Daily Sentiment (7 Days)
Articles (100)
Healthcare Stocks Are on Fire -- Don't Miss These Opportunities
Eli Lilly Highlights Positive Late-Stage Foundayo Data At Obesity Conference
Dell Technologies Stock Hits 52-Week High - Here's Why
LLY Reports Third Phase III Win for Next-Generation Obesity Drug
Eli Lilly's Triple Hormone Obesity Drug Shows Significant Weight Loss
Can Mounjaro, Zepbound & Foundayo Keep Fueling LLY's Growth Story?
GSK Stock Declines 9% in a Month: Time to Buy, Hold or Exit?
Eli Lilly vs. Merck: Which Pharma Stock Looks Stronger Now?
Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
Could Viking Therapeutics Be the Next Eli Lilly?
Best Weight Loss Drug Stocks to Buy in 2026
From Zepbound to Foundayo: Lilly's Latest Results Support Oral GLP-1 Outlook
Silver Economy Investing: Why the Healthcare Giants Are in Focus
GLP-1 Drug Giants Race to Go Global With Their Obesity Pills: ETFs to Gain
Trump's Stock Picks Perfectly Timed With New Medicare Rules: Report
Supreme Court Hands Major Blow To Big Pharma's Fight Against Biden-Era Medicare Drug Pricing Law
Watch Out, Eli Lilly and Novo Nordisk: Viking Therapeutics' Pill Could Crash the Weight-Loss Party
Eli Lilly Stock: Next Stop $2,000?
Supreme Court Rejects Eli Lilly Appeal In Medicaid Fraud Case
3 Deeply Undervalued Stocks You Can Buy for Less Than $100 Right Now
Goldman Sachs warns AI-fueled market rally is becoming ‘one big trade’
After 4 years.. i did it. +107K (realized) YTD.
Notable healthcare headlines for the week: UnitedHealth, Bristol Myers Squibb, and Hims & Hers in focus
Could Eli Lilly's Next Weight Loss Drug Waylay Wegovy -- and Even Zap Zepbound?
Lilly, Caitlin Clark Foundation, and Musco Lighting open three community sports courts in Indianapolis, expanding year-round access for youth
BIIB Advances Alzheimer's Disease Drug Despite Study Missing Main Goal
How Important Are Skyrizi and Rinvoq to AbbVie's Q1 Results?
Eli Lilly and Company (LLY) Is a Trending Stock: Facts to Know Before Betting on It
My Top 3 Healthcare Stocks for May 2026
Dominion Energy, Apple And A Health Care Stock: CNBC's 'Final Trades'
Trump 'Most Favored Nation' drug policy risks China R&D takeover
Can Novo Nordisk Sustain Its GLP-1 Edge Amid Lilly's Growing Pressure?
PFE Stock Declines Post Q1 Beat: Book Profits or Stay Invested?
Should Eli Lilly Investors Worry About Its Newest Rival -- From Within?
This Weight-Loss Drug Challenger Could Follow Eli Lilly's Playbook: Analyst
Novo Nordisk added as a new long idea at Hedgeye
Is Novo Nordisk's Rebound for Real--or Just a Head Fake?
Lilly Bets on Next-Generation Obesity Drugs to Stay Ahead
Eli Lilly Says Newly Approved Foundayo, Lower-Dose Zepbound Help Sustain Weight Loss
The Silver Tsunami: Healthcare ETFs to Buy Amid Aging US Demographics
Zacks Investment Ideas feature highlights Eli Lilly, Novo, JP Morgan, Coca-Cola, PepsiCO and Mondelez
Tremfya, Icotyde Lead J&J's Post-Stelara Immunology Strategy
GLP-1 Wars: Winners & Losers
Why Hims & Hers Health Stock Just Crashed
Roche, Eli Lilly Alzheimer's Blood Test Cleared In Europe For Earlier Detection
Peptide Wellness Market Could Near $300 Billion as Consumer Demand Accelerates
Income or Growth: Which Healthcare Stock Fits Your Portfolio Right Now?
NVO Rallies 21% in a Month: How Should Investors Play the Stock?
Merck Stock Down 7% in a Month: Should Investors Hold or Exit?
Goldman Sachs identifies the S&P 500's most committed share repurchasers
Why Eli Lilly (LLY) is a Top Momentum Stock for the Long-Term
Google’s Isomorphic Labs reportedly eyeing more than $2B in new funding round
Trump says unaware of a plan to fire FDA commissioner
Is This News From Novo Nordisk a Warning for Eli Lilly Shareholders?
Trump to fire FDA commissioner Marty Makary: WSJ
Nektar Q1 Earnings & Revenues Lag Estimates, Pipeline in Focus
Lilly weight-loss pill prescriptions said to have exceeded 7,000 in fourth week
Will Eli Lilly Be the First $2 Trillion Healthcare Stock? 3 Catalysts That Could Get It There.
Novo records a surge in Ozempic sales in India after steep price cuts: report
Dividend Roundup: Eli Lilly, PepsiCo, Apple, Visa, and more
Forget Eli Lilly: These 2 Stocks Have More Upside
Eli Lilly Now Has the World's Best-Selling Drug -- But Does That Make the Stock a No-Brainer Buy?
Here's Why Eli Lilly (LLY) is a Strong Growth Stock
The Zacks Analyst Blog Highlights Eli Lilly, Western Digital, Vertiv Holdings and AgEagle
What the FDA's Latest Proposal Means for Lilly, Novo, and Hims
Eli Lilly To Invest $4.5 Billion More In Indiana Manufacturing Sites
My Top Obesity Stock to Buy and Hold
Top Research Reports for Eli Lilly, Western Digital & Vertiv
LLY Stock Pops 16% After Beat-and-Raise Q1: Buy, Hold or Take Profits?
Lilly to spend $4.5B to expand manufacturing at two Indiana sites
Trump's Drug Pricing Deals Could Lead To $529 Billion Savings For The Economy Over The Decade: Report
Novo Nordisk says oral Wegovy success to soften sales decline
Robert F. Kennedy Jr. Wants To Take 'Clear And Decisive Action' On Psychiatric Drugs Amid 'Deprescribing' Push: Big Pharma Should Pay Attention
Lilly's Oral GLP-1 Pill Foundayo Starts Strong in Oral Obesity Market
Novo Nordisk earnings seen as inflection point amid GLP-1 pricing reset
Eli Lilly Advances As Inflammatory Bowel Disease Drug Reinforces Long-Term Confidence
3 Reasons It's Not Too Late to Buy Eli Lilly Stock
Is Eli Lilly Stock Heading for $1,000?
3 Absurdly Cheap Growth Stocks to Buy in May 2026
Here's Exactly Why Wall Street Thinks Viking Therapeutics Stock Could Soar 207% Over the Next 12 Months
The Most Surprising Thing About Eli Lilly's Impressive Revenue Growth: Just How Much More Potential There Is
ABBV Stock Up 5% on Robust Q1 Performance: Time to Buy, Sell or Hold?
Novo Nordisk Before Q1 Earnings: How Should Investors Play the Stock?
Eli Lilly declares $1.73 dividend
Lilly shares under pressure after serious Foundayo adverse event report
Most and least shorted mid-to mega-cap healthcare stocks in May
Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know
GLP-1 Boom Sparks Potential 'Bubble Effect,' Shrinking Competition In Big Pharma, Warns Deloitte: 'The Question Is...'
Cabaletta Bio prices $150M stock offering
Eli Lilly Just Announced Fantastic News for Shareholders
Why Eli Lilly Stock Jumped This Week
Pfizer Stock: Still Priced Like It's Dead Money
Key deals this week: Organon, ARC Resources, Nebius, Eli Lilly and more
Notable healthcare headlines for the week: Merck, Eli Lilly, and GE HealthCare in focus
Healthcare earnings impress with 86% beat rate, yet sector lags: Earnings Scorecard
Earnings Scoreboard: 82% of S&P 500 reporting firms top EPS estimates as 78% of firms post Y/Y earnings growth
Vest Financial LLC Reduces Stock Position in Eli Lilly and Company $LLY - MarketBeat
5 Stocks Investors Couldn't Stop Buzzing About This Week: AAPL, GOOG, HOOD And More
S&P 500's Best‑Kept Secret: Why Healthcare Could Be 2026's Breakout Winner
Lilly's oral weight loss pill Foundayo surpasses 5600 scripts in third week